Interaction between the UCP2 -866 G>A polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromes

Authors

Amber L. Beitelshees, University of Maryland - BaltimoreFollow
Brian N. Finck, Washington University School of Medicine in St. Louis
Teresa C. Leone, Washington University School of Medicine in St. LouisFollow
Sharon Cresci, Washington University School of Medicine in St. Louis
Jun Wu, Burnham Institute for Medical Research at Lake Nona
Michael A. Province, Burnham Institute for Medical Research at Lake Nona
Elisa Fabbrini, Washington University School of Medicine in St. Louis
Erik P. Kirk, Washington University School of Medicine in St. LouisFollow
Issam Zineh, University of Florida College of Pharmacy
Samuel Klein, Washington University School of Medicine in St. LouisFollow
John A. Spertus, University of Missouri - Kansas City
Daniel P. Kelly, Washington University School of Medicine in St. Louis

Areas of Expertise

Sharon Cresci, 2050 Genomics; Elisa Fabbrini, 6840 Metabolic Diseases; Erik P. Kirk, 7100 Surgery; Samuel Klein, 3100 Nutritional Sciences

Journal

Pharmacogenetics and Genomics

Volume

20

Issue

4

Document Type

Article

Pages

231-238

Publication Date

2010

Recommended Citation

Beitelshees, Amber L.; Finck, Brian N.; Leone, Teresa C.; Cresci, Sharon; Wu, Jun; Province, Michael A.; Fabbrini, Elisa; Kirk, Erik P.; Zineh, Issam; Klein, Samuel; Spertus, John A.; and Kelly, Daniel P., "Interaction between the UCP2 -866 G>A polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromes". Pharmacogenetics and Genomics, 231-238. 2010. Paper 30.
https://digitalcommons.wustl.edu/icts_facpubs/30